# Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

> **NCT06217094** · PHASE1 · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** NP-101 (3 g)
- **DRUG:** NP-101 (4.8 g)
- **DRUG:** NP-101 (6 g)

## Key facts

- **NCT ID:** NCT06217094
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-02
- **Primary completion:** 2028-07
- **Final completion:** 2030-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding terminated
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217094, "Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06217094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*